Cargando…

Tocilizumab for hospitalized patients with COVID-19

Detalles Bibliográficos
Autores principales:	Afra, Kevin, Chen, Luke Y.C., Sweet, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Joule Inc. 2021
Materias:	Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087334/ https://www.ncbi.nlm.nih.gov/pubmed/33692091 http://dx.doi.org/10.1503/cmaj.210066

Ejemplares similares

Le tocilizumab pour les patients hospitalisés atteints de la COVID-19
por: Afra, Kevin, et al.
Publicado: (2021)

Innovations in genomics for undiagnosed diseases: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome
por: Stubbins, Ryan J., et al.
Publicado: (2022)

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
por: Stone, John H., et al.
Publicado: (2020)

Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study
por: Stukas, Sophie, et al.
Publicado: (2022)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature
por: Bernardo, Luca, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
por: Rutgers, Abraham, et al.
Publicado: (2022)

Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study
por: Anci, Cynthia, et al.
Publicado: (2023)

Tocilizumab for treatment of mechanically ventilated patients with COVID-19
por: Somers, Emily C, et al.
Publicado: (2020)

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
por: Somers, Emily C, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in COVID-19 patients
por: Zheng, Kai-Lian, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

Time for tocilizumab in COVID-19?
por: Butler, Ethan, et al.
Publicado: (2021)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Building resilient hospitals in the Eastern Mediterranean Region: lessons from the COVID-19 pandemic
por: Khalil, Merette, et al.
Publicado: (2022)

Application of Machine Learning in Hospitalized Patients with Severe COVID-19 Treated with Tocilizumab
por: Ramón, Antonio, et al.
Publicado: (2022)

Tu1265: LIVER INJURY IN HOSPITALIZED COVID-19 PATIENTS TREATED WITH TOCILIZUMAB
por: Kalligeros, Markos, et al.
Publicado: (2022)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
por: Wang, Yong, et al.
Publicado: (2022)

Tocilizumab and liver injury in patients with COVID-19
por: Serviddio, Gaetano, et al.
Publicado: (2020)

Thromboinflammation response to tocilizumab in COVID‐19
por: Gergi, Mansour, et al.
Publicado: (2020)

Antithrombotic agents in patients with COVID-19
por: Khan, Faizan, et al.
Publicado: (2022)

Novel strategies to support global promotion of COVID-19 vaccination
por: Wood, Stacy, et al.
Publicado: (2021)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study
por: Martínez-Sanz, Javier, et al.
Publicado: (2021)

Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials
por: Selvaraj, Vijairam, et al.
Publicado: (2021)

400. Secondary Infections in COVID-19 Patients Receiving Tocilizumab in a Community Hospital
por: Usiak, Shauna, et al.
Publicado: (2020)

Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
por: Khatib, Mohamad Y., et al.
Publicado: (2020)

Evaluation of dedicated COVID-19 hospitals in the pandemic response in Iraq: pandemic preparation within a recovering healthcare infrastructure
por: Hossain, S M Moazzem, et al.
Publicado: (2022)

Tocilizumab in COVID-19: Is the Temptation Worthwhile?
por: Gupta, Sachin, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85vms7e4jn2f14rpug9e14d1en